Pfizer (PFE) says its Covid-19 vaccine contributed $12.5B in direct sales for 4Q. Vamil Divan, Senior Biopharmaceuticals Research Analyst at Mizuho Americas, and David Toung, Senior Analyst of Health Care at Argus Research, recaps PFE’s earnings. They discuss how PFE is lower after reporting a miss on revenue. Mizuho has a neutral rating on PFE with a $56 price target. Tune in to find out more.
08 Feb 2022
Trading 360
23 Feb 2022
Morning Trade Live
18 Mar 2022
Market On Close
23 Feb 2022
Trading 360
18 Apr 2022
Trading 360
28 Apr 2022
Market On Close
05 Apr 2022